1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Essex Bio-Technology Limited

Essex Bio-Technology Limited

HHKEX:1061
2.02
HKD
-0.01
(-0.74%)
1.51BMarket Cap
Mar 11Next Earn
Essex Bio-Technology Limited
HKEX:1061
(Hong Kong Exchange)

Recent

price

2.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
0.26
0.38
0.48
0.62
0.93
1.17
1.38
1.6
2.06
2.21
1.69
2.84
2.3
3.05
2.94
3.2
- -
Revenue per Share
0.05
0.06
0.07
0.1
0.14
0.19
0.24
0.3
0.4
0.52
0.38
0.6
0.39
0.48
0.54
0.56
- -
Basic EPS, GAAP
0.03
-0.04
-0.12
0.04
0.03
0.08
0.1
0.23
0.18
0.12
-0.03
0.27
0.17
0.37
0.44
0.23
- -
Free Cash Flow per Basic Share
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.06
0.06
0.07
0.05
0.09
0.09
0.07
0.1
0.13
- -
Dividend per Share
0.24
0.29
0.35
0.46
0.59
0.74
0.99
1.31
1.61
2.07
2.47
3.01
3.03
3.39
3.74
4.26
4.5
Book Value per Share
0.21
0.26
0.32
0.41
0.53
0.66
0.84
1.05
1.19
1.35
1.39
1.55
1.19
1.41
1.64
1.9
2.09
Tangible Book Value per Share
557
557
557
557
557
560
560
562
571
579
578
577
574
570
567
567
567
Basic Weighted Avg Shares
146
213
267
347
518
654
776
900
1,176
1,279
978
1,638
1,318
1,737
1,670
1,814
- -
Sales/Revenue/Turnover
21.33
18.33
18.68
21.57
19.17
20.23
21.33
20.98
22.11
25.71
22.51
25.21
21.36
19.25
21.26
22.79
- -
Operating Margin (%)
2
1
1
3
10
10
13
18
20
28
28
33
42
60
56
63
- -
Depreciation Expense
27
33
39
55
75
105
136
167
231
303
219
346
225
275
307
318
- -
Net Income, GAAP
14.79
17.26
21.46
24.86
21.39
19.71
16
15.1
15.37
14
12.73
12.29
13.42
20.45
18.18
23.29
- -
Effective Tax Rate (%)
18.17
15.61
14.59
15.82
14.52
16.04
17.57
18.6
19.64
23.64
22.38
21.13
17.11
15.85
18.4
17.54
- -
Profit Margin (%)
101
86
27
47
124
151
312
438
547
758
727
858
653
435
574
853
905
Working Capital
- -
- -
- -
- -
- -
- -
121
129
189
350
360
409
382
56
114
278
249
LT Debt
132
163
196
254
331
413
557
739
929
1,197
1,426
1,734
1,731
1,924
2,124
2,413
2,549
Total Equity
21.79
21.06
17.49
19.26
22.57
25.04
24.19
21.29
21.35
20.71
10.38
16.61
9.09
11.48
12.75
11.85
- -
Return on Invested Capital (%)
22.12
22.47
18.61
19.63
22.81
25.2
24.46
21.72
23.55
22.98
12.38
16.51
10.41
12.8
13.79
12.78
- -
Return on Capital (%)
22.12
22.47
21.69
24.38
25.73
28.2
28.11
25.81
27.7
28.46
16.69
21.89
13.01
15.06
15.18
14.02
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
123
69
100
LT Borrowings
150
261
230
LT Finance Leases
17
17
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
567
567
566
Market Capitalization
2,500
2,138
1,511

Working Capital

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,442
1,620
1,689
Cash, Cash Equivalents & STI
643
784
808
Accounts Receivable, Net
614
657
669
Inventories
65
79
87
Total Current Liabilities
758
767
784
Payables & Accruals
- -
- -
- -
ST Debt
123
69
100
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.78%
11.31%
13.63%
Free Cash Flow
-91.92%
-178.25%
-47.1%
Net Income, GAAP
15.45%
12.09%
3.54%
Sales/Revenue/Turnover
13.5%
16.89%
8.62%
Total Cash Common Dividend
27.09%
26.17%
23.71%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,670
2025
- -
- -
1,814
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.54
2025
- -
- -
0.56
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.1
2025
- -
- -
0.13
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Essex Bio-Technology Limited (1061.HK) develops, manufactures, and commercializes biopharmaceutical products focused on wound care, ophthalmology, and cardiovascular health. The company offers a portfolio of proprietary products including recombinant human acidic fibroblast growth factor gel (AFGF) for chronic wound healing under the Fiblast brand; nerve growth factor eye drops (NGF) for dry eye and neurotrophic keratitis under the Befiter brand; and recombinant human serum albumin for medical applications; alongside distribution of third-party products such as anti-bacterial artificial dermis, hyaluronic acid dermal fillers, and cardiovascular devices. Essex operates primarily in China with expanding presence in Hong Kong, Macau, and select international markets including Southeast Asia and Europe, targeting hospitals, clinics, and pharmaceutical distributors.[web:previous] Founded in 2004 and headquartered in Causeway Bay, Hong Kong, the company maintains research and development facilities and manufacturing sites in Zhuhai, China, through its subsidiaries Essex Zhuhai Bio-Technology Co., Ltd. and Essex Bio-Investment Ltd. Essex serves healthcare professionals and patients in dermatology, ophthalmology, and regenerative medicine segments, emphasizing innovative biologic therapies derived from recombinant protein technology.[web:previous] In recent developments, Essex Bio-Technology reported robust revenue growth in 2024, driven by strong demand for its core wound care and ophthalmology products amid China's aging population and healthcare reforms. The company expanded its product pipeline with regulatory approvals for new indications of NGF eye drops and advanced clinical trials for cardiovascular biologics as of mid-2025. Additionally, Essex strengthened its market position through strategic distribution partnerships in Southeast Asia and ongoing investments in manufacturing capacity upgrades in Zhuhai to support export growth.[web:previous]